BRTX logo

BioRestorative Therapies (BRTX) EBITDA

Annual EBITDA

-$14.97 M
+$3.77 M+20.12%

December 1, 2023


Summary


Performance

BRTX EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherBRTXprofitabilitymetrics:

Quarterly EBITDA

-$2.24 M
+$182.40 K+7.53%

September 1, 2024


Summary


Performance

BRTX Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherBRTXprofitabilitymetrics:

TTM EBITDA

-$11.90 M
+$740.30 K+5.85%

September 1, 2024


Summary


Performance

BRTX TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherBRTXprofitabilitymetrics:

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

BRTX EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+20.1%+24.9%+27.2%
3 y3 years-57.4%+43.9%+54.6%
5 y5 years-65.3%+43.9%+54.6%

BRTX EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+42.9%at high+61.0%at high+54.6%
5 y5-year-61.1%+42.9%-176.5%+85.1%-158.0%+57.1%
alltimeall time-640.8%+42.9%-176.5%+85.1%-3115.6%+57.1%

BioRestorative Therapies EBITDA History

DateAnnualQuarterlyTTM
Sep 2024
-
-$2.24 M(-7.5%)
-$11.90 M(-5.9%)
Jun 2024
-
-$2.42 M(-40.5%)
-$12.64 M(-4.9%)
Mar 2024
-
-$4.07 M(+28.0%)
-$13.30 M(-11.2%)
Dec 2023
-$14.97 M(-20.1%)
-$3.18 M(+6.7%)
-$14.97 M(-8.4%)
Sep 2023
-
-$2.98 M(-3.1%)
-$16.35 M(-8.9%)
Jun 2023
-
-$3.08 M(-46.4%)
-$17.95 M(-7.8%)
Mar 2023
-
-$5.74 M(+26.0%)
-$19.47 M(+3.9%)
Dec 2022
-$18.74 M(-28.5%)
-$4.56 M(-0.5%)
-$18.74 M(+3.1%)
Sep 2022
-
-$4.58 M(-0.4%)
-$18.17 M(+5.3%)
Jun 2022
-
-$4.60 M(-8.3%)
-$17.26 M(+6.6%)
Mar 2022
-
-$5.01 M(+25.7%)
-$16.20 M(-38.2%)
Dec 2021
-$26.22 M(+175.7%)
-$3.99 M(+8.7%)
-$26.22 M(-5.5%)
Sep 2021
-
-$3.67 M(+3.8%)
-$27.74 M(+11.7%)
Jun 2021
-
-$3.53 M(-76.5%)
-$24.84 M(+35.1%)
Mar 2021
-
-$15.03 M(+172.9%)
-$18.38 M(+93.4%)
Dec 2020
-$9.51 M(+2.4%)
-$5.51 M(+617.0%)
-$9.50 M(+106.0%)
Sep 2020
-
-$768.20 K(-126.2%)
-$4.61 M(-33.8%)
Jun 2020
-
$2.93 M(-147.5%)
-$6.96 M(-45.1%)
Mar 2020
-
-$6.15 M(+897.2%)
-$12.68 M(+36.4%)
Dec 2019
-$9.29 M(+2.6%)
-$617.20 K(-80.2%)
-$9.29 M(-19.2%)
Sep 2019
-
-$3.12 M(+12.0%)
-$11.50 M(+10.1%)
Jun 2019
-
-$2.79 M(+0.5%)
-$10.45 M(+6.6%)
Mar 2019
-
-$2.77 M(-1.9%)
-$9.80 M(+8.2%)
Dec 2018
-$9.06 M(+11.8%)
-$2.82 M(+36.7%)
-$9.06 M(+18.8%)
Sep 2018
-
-$2.07 M(-3.5%)
-$7.62 M(+4.9%)
Jun 2018
-
-$2.14 M(+5.8%)
-$7.27 M(-4.7%)
Mar 2018
-
-$2.02 M(+45.4%)
-$7.63 M(-5.8%)
Dec 2017
-$8.10 M
-$1.39 M(-18.7%)
-$8.10 M(-4.9%)
DateAnnualQuarterlyTTM
Sep 2017
-
-$1.71 M(-31.6%)
-$8.52 M(+0.4%)
Jun 2017
-
-$2.50 M(+0.5%)
-$8.48 M(+5.2%)
Mar 2017
-
-$2.49 M(+37.6%)
-$8.06 M(+5.9%)
Dec 2016
-$7.61 M(+7.1%)
-$1.81 M(+8.0%)
-$7.61 M(-10.0%)
Sep 2016
-
-$1.68 M(-19.6%)
-$8.46 M(+2.3%)
Jun 2016
-
-$2.08 M(+1.9%)
-$8.27 M(+10.3%)
Mar 2016
-
-$2.05 M(-23.1%)
-$7.50 M(+5.5%)
Dec 2015
-$7.11 M(+36.5%)
-$2.66 M(+79.4%)
-$7.11 M(+21.6%)
Sep 2015
-
-$1.48 M(+13.1%)
-$5.84 M(+8.9%)
Jun 2015
-
-$1.31 M(-20.9%)
-$5.36 M(+1.4%)
Mar 2015
-
-$1.66 M(+18.6%)
-$5.29 M(+1.6%)
Dec 2014
-$5.21 M(-1.3%)
-$1.40 M(+39.4%)
-$5.21 M(-2.3%)
Sep 2014
-
-$1.00 M(-18.9%)
-$5.33 M(-3.9%)
Jun 2014
-
-$1.24 M(-21.3%)
-$5.55 M(+0.8%)
Mar 2014
-
-$1.57 M(+3.4%)
-$5.50 M(+4.4%)
Dec 2013
-$5.28 M(-9.9%)
-$1.52 M(+24.5%)
-$5.28 M(-9.1%)
Sep 2013
-
-$1.22 M(+2.4%)
-$5.80 M(+0.7%)
Jun 2013
-
-$1.19 M(-11.1%)
-$5.76 M(-4.6%)
Mar 2013
-
-$1.34 M(-34.5%)
-$6.04 M(+0.0%)
Dec 2012
-$5.85 M(+57.2%)
-$2.05 M(+73.9%)
-$6.04 M(+30.8%)
Sep 2012
-
-$1.18 M(-19.9%)
-$4.62 M(+6.1%)
Jun 2012
-
-$1.47 M(+9.7%)
-$4.35 M(+8.8%)
Mar 2012
-
-$1.34 M(+113.5%)
-$4.00 M(+7.4%)
Dec 2011
-$3.72 M(+84.2%)
-$628.10 K(-31.2%)
-$3.72 M(-12.3%)
Sep 2011
-
-$913.10 K(-18.3%)
-$4.25 M(+14.7%)
Jun 2011
-
-$1.12 M(+5.1%)
-$3.70 M(+43.3%)
Mar 2011
-
-$1.06 M(-7.5%)
-$2.58 M(+70.0%)
Dec 2010
-$2.02 M
-$1.15 M(+210.7%)
-$1.52 M(+310.7%)
Sep 2010
-
-$370.20 K
-$370.20 K

FAQ

  • What is BioRestorative Therapies annual EBITDA?
  • What is the all time high annual EBITDA for BioRestorative Therapies?
  • What is BioRestorative Therapies annual EBITDA year-on-year change?
  • What is BioRestorative Therapies quarterly EBITDA?
  • What is the all time high quarterly EBITDA for BioRestorative Therapies?
  • What is BioRestorative Therapies quarterly EBITDA year-on-year change?
  • What is BioRestorative Therapies TTM EBITDA?
  • What is the all time high TTM EBITDA for BioRestorative Therapies?
  • What is BioRestorative Therapies TTM EBITDA year-on-year change?

What is BioRestorative Therapies annual EBITDA?

The current annual EBITDA of BRTX is -$14.97 M

What is the all time high annual EBITDA for BioRestorative Therapies?

BioRestorative Therapies all-time high annual EBITDA is -$2.02 M

What is BioRestorative Therapies annual EBITDA year-on-year change?

Over the past year, BRTX annual EBITDA has changed by +$3.77 M (+20.12%)

What is BioRestorative Therapies quarterly EBITDA?

The current quarterly EBITDA of BRTX is -$2.24 M

What is the all time high quarterly EBITDA for BioRestorative Therapies?

BioRestorative Therapies all-time high quarterly EBITDA is $2.93 M

What is BioRestorative Therapies quarterly EBITDA year-on-year change?

Over the past year, BRTX quarterly EBITDA has changed by +$740.30 K (+24.85%)

What is BioRestorative Therapies TTM EBITDA?

The current TTM EBITDA of BRTX is -$11.90 M

What is the all time high TTM EBITDA for BioRestorative Therapies?

BioRestorative Therapies all-time high TTM EBITDA is -$370.20 K

What is BioRestorative Therapies TTM EBITDA year-on-year change?

Over the past year, BRTX TTM EBITDA has changed by +$4.45 M (+27.19%)